Abstract | BACKGROUND: CASE PRESENTATION: Here we present the case of a patient with cervical cancer treated in this setting. A 49-year-old woman diagnosed with International Federation of Obstetricians and Gynecologists stage 2018 IIIC2 locally advanced undifferentiated cervical cancer received first-line chemoradiotherapy followed by carboplatin, paclitaxel, and bevacizumab with partial response. Because of a family history of cancers, the patient was tested and found positive for a pathogenic BRCA1 germline and somatic mutation, which motivated bevacizumab plus olaparib maintenance treatment. A simple hysterectomy was performed after 2 years stable disease; pathological report showed complete pathological response, and 12 months follow-up showed no recurrence. CONCLUSION:
|
Authors | Rosa Montero-Macias, Meriem Koual, Céline Crespel, Marie Aude Le Frére-Belda, Hélène Blons Hélène, Huyen-Thu Nguyen-Xuan, Simon Garinet, Géraldine Perkins, Vincent Balay, Catherine Durdux, Marie Florin, Hélène Péré, Anne-Sophie Bats |
Journal | Journal of medical case reports
(J Med Case Rep)
Vol. 15
Issue 1
Pg. 210
(Apr 23 2021)
ISSN: 1752-1947 [Electronic] England |
PMID | 33888155
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- BRCA1 Protein
- BRCA1 protein, human
- Phthalazines
- Piperazines
- Bevacizumab
- olaparib
|
Topics |
- BRCA1 Protein
(genetics)
- Bevacizumab
(therapeutic use)
- Chemoradiotherapy
- Female
- Humans
- Middle Aged
- Mutation
- Neoplasm Recurrence, Local
(drug therapy)
- Ovarian Neoplasms
(drug therapy)
- Phthalazines
- Piperazines
- Uterine Cervical Neoplasms
(drug therapy, genetics)
|